Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC NN1177 (TFA) | 98.7% | 4570.07 (free base) | 5 MG
NN1177 TFA (NNC9204-1177 TFA) is a long-acting GLP-1/glucagon receptor co-agonist. This compound is known to induce dose-dependent body weight loss in diet-induced obese mice and improves glucose tolerance. It has also been shown to reduce liver fat and relevant inflammatory and fibrosis biomarkers in NASH models.
- Long-acting GLP-1/glucagon receptor co-agonist
- Induces body weight loss
- Improves glucose tolerance
- Reduces liver fat
- Reduces inflammatory and fibrosis relevant biomarkers
- For research use only
Medchemexpress LLC Cpp12 (Tfa) | 98.69% | 1700.55 | 1 MG
CPP12 TFA is a small, amphiphilic, cyclic cell-penetrating peptide (CPP) in salt form. It binds directly to plasma membrane phospholipids, enters mammalian cells via endocytosis, and is then efficiently released from endosomes. It can be used for intracellular delivery of drugs and chemical probes.
- Small, amphiphilic, cyclic cell-penetrating peptide (CPP)
- Binds directly to plasma membrane phospholipids
- Enters mammalian cells via endocytosis
- Efficiently released from endosomes
- Can be used for intracellular delivery of drugs and chemical probes
Medchemexpress LLC TP-5801 (TFA) | 99.6% | 641.48 | 25 MG
TP-5801 TFA is an orally active TNK1 (non-receptor tyrosine kinase) inhibitor with an IC50 of 1.40 nM. This compound demonstrates anti-tumor activity and is suitable for various research applications.
- Inhibits TNK1-driven, BCR-ABL-driven, and IL-3-driven Ba/F3 cell growth.
- Inhibits TNK1-dependent L540 cell growth at low nM levels.
- Shows efficacy in mouse survival models, significantly prolonging lifespan.
- Inhibits localized tumor growth in mouse xenograft models.
Medchemexpress LLC AS-99 TFA | 99.1% | C29H31F6N5O5S2 | 1 MG
AS-99 TFA is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC50 of 0.79 μM, Kd of 0.89 μM) with anti-leukemic activity. It functions by blocking cell proliferation, inducing apoptosis and differentiation, downregulating MLL fusion target genes, and reducing the leukemia burden in vivo.
- Potent and selective ASH1L histone methyltransferase inhibitor
- Demonstrates anti-leukemic activity
- Blocks cell proliferation
- Induces apoptosis and differentiation
- Downregulates MLL fusion target genes
- Reduces leukemia burden in vivo
- Exhibits over 100-fold selectivity towards ASH1L over 20 other histone methyltransferases
- Suppresses MLL fusion driven transcriptional programs
- Leads to dose-dependent downregulation of canonical MLL fusion target genes
